



DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors

Marseille, France, September 9, 2024 – DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Eleanor L. Ramos, MD, as an Independent Board Member.

“Dr. Ramos brings invaluable expertise in the development of novel treatments for type 1 diabetes (T1D), having participated in the regulatory approval of teplizumab-mzwv, the first disease-modifying treatment for the delay of stage 3 T1D,” said Benjamin Charles, CEO of DiogenX. “With our lead candidate DGX-01 having entered IND-enabling studies, we are now preparing the next steps and Dr Ramos’ clinical expertise is a fantastic addition to the team.”

The company’s lead candidate, DGX-01, is a first-in-class recombinant protein that aims at replicating insulin-producing beta cells in the pancreas. This novel approach has the potential to offer a disease-modifying therapy for T1D, a chronic and life-threatening condition that affects millions of people worldwide. It is currently undergoing IND-enabling studies.

Dr. Eleanor L. Ramos, MD, Independent Board Member

Dr. Ramos brings to DiogenX a wealth of clinical expertise in autoimmunity, inflammation, organ transplant rejection and the treatment of acute and chronic viral infections. Notably, she served as Chief Medical Officer at Provention Bio, an immunology-focused company acquired by Sanofi in 2023, where she played an instrumental role in the approval of teplizumab-mzwv, the first disease-modifying treatment for the delay of Stage 3 T1D. Previously Dr. Ramos held Chief Medical Officer positions in several biotechnology companies, including Global Blood Therapeutics, Theraclone Sciences, where she oversaw the development of clinical programs in viral diseases such as severe influenza, and ZymoGenetics, where she managed a clinical portfolio in infectious diseases (hepatitis C), immunology (lupus nephritis), oncology and hemostasis.

Dr. Ramos is currently a member of the Scientific Advisory Board at EpiVax Oncology, a private biotechnology company focused on developing personalized cancer vaccines. Her experience also encompasses leading the Clinical Trials Group at the Immune Tolerance Network (ITN), a collaborative network for clinical research funded by the National Institute of Allergy and Infectious Diseases (NIAID). She holds a medical degree and undergraduate degree from Tufts University, along with advanced training in the subspecialty of nephrology with a focus on transplantation immunology at Brigham and Women’s Hospital, Harvard Medical School (Boston, USA).

“I am delighted to join the Board of DiogenX,” said Dr. Ramos. “I look forward to leveraging my expertise and experience in T1D to support the company in its vision following its successful Series A investment round. DiogenX has unveiled promising preclinical work and I am excited to be involved in the development of a therapy that has the potential to prevent and reverse T1D.”



About DiogenX

DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes.

Founded in 2020, its work is based on the pancreatic beta cell regeneration research of leading Type 1 Diabetes (T1D) scientist Patrick Collombat. The company is developing first-in-class recombinant proteins designed for the treatment of T1D. DiogenX's lead program DGX-01 modulates the Wnt/ β -catenin signalling pathway to regenerate insulin-producing pancreatic beta cells to offer a disease-modifying therapy for T1D. This program is currently undergoing IND-enabling studies.

DiogenX is supported by a network of world-leading experts in diabetes and a consortium of investors including diabetes and biopharma leaders Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly and Company, Omnes, Sunstone Capital, T1D Fund and AdBio partners.

The company, co-founded by Patrick Collombat, Jean-Pascal Tranié and Benjamin Charles, is based in Marseille, France, with research labs in Nice, France.

www.diogenx.com

Media and analysts contacts

Andrew Lloyd & Associates

Saffiyah Khalique – Celine Gonzalez

saffiyah@ala.associates / celine@ala.associates

UK: +44 1273 952 481

US: +1 203 724 5950